Abstract:OBJECTIVE:To investigate the effects of transfection of human plasminogen Kringle 5 gene on pancreatic cancer.METHODS:Human pancreatic cancer cells of the line PC-3 were cultured. Recombinant plasmid RINGLE 5 containing human plasminogen Kringle 5 cDNA was transfected into the PC-3 cells mediated by lipodectAMINE. RT-PCR was used to detect the expression of Kringle 5. Another 2 groups of PC3 cells: PC3 cells cultured in pure culture medium and those transfected with blank plasmids were used as controls. MTT method was used to draw the growth curves of cells. Immunohistochemistry was used to detect the expression of Kringle 5. Flow cytometry was used to observe the cell cycle and apoptosis. The morphology of cells was observed by transmission electron microscopy. Human umbilical vein endothelial cells ECV304 at logarithmic growth phase were cultured and the supernatants of the 3 groups of PC3 cells were added into the culture fluid respectively. MTT method was used to detect the absorbance and draw the growth curves. Twenty-one BALB/c nude mice were randomly divided into 3 groups of 7 mice to be inoculated with these 3 different PC3 cells. The appearance and size of tumor were observed continuously.RESULTS:Kringle 5 was expressed in the PC3 cells transfected with Kringle 5. The proliferation in the PC3 cells transfected with Kringle 5 became significantly lower compared with the other groups of PC3 cells 3 or 7 days respectively after transfection (P = 0.045 or P = 0.038). Four days after the addition of the different kinds of supernatant the ECV304 cells grew significantly slower in the Kringle 5 group than in the other 2 groups (P = 0.041). Immunohistochemistry showed high expression of Kringle 5 protein in the PC3 cells transfected with Kringle 5 and very weak expression in other 2 groups. The apoptotic indices of the PC3 cells, PC3/PUCKRINGLE 5 cells, and PC3/Kringle 5 cells were 6.6% +/- 1.3%, 7.3% +/- 0.9%, and 12.1% +/- 2.3% respectively (P = 0.045). The S stage change rates of the PC3 cells, PC3/PUCKRINGLE 5cells, and PC3/Kringle 5 cells were 33.3% +/- 3.7%, 19.4% +/- 2.4%, and 7.4% +/- 3.3% respectively. Transmission electron microscopy showed significant apoptosis in the PC3 cells transfected with Kringle 5 gene. Since the 5th week after inoculation the tumor grew significantly slower in the Kringle 5 group than in the other 2 groups (P = 0.032). Since the 7th week the tumor growth remarkably slowed down (P = 0.05).CONCLUSION:PC3 cell successfully transfected with K5 gene can potently inhibits endothelial cell proliferation and the growth of pancreatic cancer in nude mouse. The study provides a promise for the anti-angiogenesis gene therapy in vivo.

Studying and Progression of Human Plasminogen Kringle 5

BIOMEDICAL APPLICATION OF K5 PLASMINOGEN FRAGMENT

[Effects of Human Plasminogen Kringle 5 Gene Therapy on Pancreatic Cancer].

[Preparation and Functional Study of an Adenovirus Vector Expressing Human Plasminogen Kringle 5 Gene].

Angio-3, a 10-Residue Peptide Derived from Human Plasminogen Kringle 3, Suppresses Tumor Growth in Mice Via Impeding Both Angiogenesis and Vascular Permeability

Inhibitory effects of plasminogen K5 combined chemotherapy and radiotherapy on S180 solid tumor in mice

High Efficacy and Minimal Peptide Required for the Anti-Angiogenic and Anti-Hepatocarcinoma Activities of Plasminogen K5.

Experimental study of 188Re labeled RGD tumor homing peptide modified recombinant human plasminogen kringle5

Molecular recognition and interaction between human plasminogen Kringle 5 and voltage-dependent anion channel-1 by biological specificity technologies and molecular dynamic simulation

Progress in Studies of Angio- Statin and Its Anti-Tumor Effects

Molecular recognition and interaction between human plasminogen Kringle 5 and A2M domain in human complement C5 by biospecific methods coupled with molecular dynamics simulation

Screening, characterization and specific binding mechanism of aptamers against human plasminogen Kringle 5

In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2.

Anti-fibrosis Effect of Nanoparticle-Mediated Delivery of Plasminogen Kringle 5.

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2.

Radioiodine Labelling Recombinant Human Plasminogen Kringle5 and Its Tumor Imaging

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis

Anti-inflammatory and Antiangiogenic Effects of Nanoparticle-Mediated Delivery of a Natural Angiogenic Inhibitor

Research Progress of Antiangiogenic in Breast Cancer Therapy

Systemic Inhibition of Tumor Growth by Soluble Flk-1 Gene Therapy Combined with Cisplatin